Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Lakefront Biotherapeutics NV

LKFT · Nasdaq · USD · Market cap $2.3B

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

FAIL · Does not pass the screen
33.31 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price33.31 USD at the 20 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 20 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 10.62)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $20.91 to $44.63, base estimate $26.92 (screen dated 2026-11-20).

Current read
Accumulation ?
Overvalued · screened 2026-11-20
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 10.62, read 2026-11-15
  • Ethical does not pass the values gate
Price33.31 USD
Fair value26.92
Ethical score70.0/100
Value readOvervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-10-17Read Accumulation29.05+14.7% to today ✓Markup gives way to Accumulation first Accumulation read since August
2026-09-04Read Markup29.44+13.1% to today ✓Accumulation gives way to Markup
2026-08-04Read Accumulation30.01+11.0% to today ✓Distribution gives way to Accumulation
2026-07-02Read Distribution28.90+15.3% to today First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Lakefront Biotherapeutics NV holds its Accumulation at $33.31. The statistical read favours the buyers, held for 135 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateThe statistical read favours the buyers, held for 135 days
Price at the screen$33.31
Valuation2.47 trailing · -22.08 forward price to earnings
Values screenFAIL · score 70.0
Beta0.01
The Workings

Five Screens: LKFT's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.20% Below 33% Pass
Interest-bearing cash 85.43% Below 33% Fail
Receivables 2.86% Below 49% Pass
Revenue purity 4.17% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Lakefront Biotherapeutics's business is fine, but its cash and interest-bearing securities are about 85% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when LKFT's ethical verdict changes

Today LKFT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued to fair value, as of 20 Nov 2026: it trades above our $26.92 fair value estimate.

Method.

20.91Conservative26.92Base case44.63Growth case 33.31Price

USD, 2026-11-20 screen. The price runs 23.7% over base.

The Street's Range
20.91Street low 26.92Street average 44.63Street high 33.31Price

Street: 3 covering, consensus Hold. Average target −19%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-22.1x
Trailing P/E2.5xvery cheap relative to earnings
EPS, trailing13.94
EPS, forward-1.56
Revenue growth-81.5%revenue is shrinking
Profit margin60.2%highly profitable on every dollar of sales
Return on equity20.1%an exceptional return on shareholder capital
FCF yield6.10%
Debt to equity0.20minimal debt: a conservative balance sheet
Current ratio32.84comfortably covers its short-term bills
Beta0.01barely tracks the market's swings
Short interest, float0.03%
52-week range25.68 - 36.24
Market cap$2.3B

LKFT-specific watchpoints · The things to watch: its business and earnings are exposed to Belgium and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $34.07 +0.3% Entry 12
2026-11-14 Accumulation $33.98 +1.6% Entry 11
2026-11-07 Accumulation $33.45 +5.7% Entry 10
2026-10-31 Accumulation $31.65 +3.5% Entry 9
2026-10-24 Accumulation $30.58 +5.3% Entry 8
2026-10-17 Accumulation · changed $29.05 -1.8% Entry 7

The framework has shifted from markup to accumulation since the last review.

2026-10-02 Markup $29.59 +0.5% Entry 6
2026-09-04 Markup · changed $29.44 -1.9% Entry 5

The framework has shifted from accumulation to markup since the last review.

2026-08-04 Accumulation · changed $30.01 +3.8% Entry 4

The framework has shifted from distribution to accumulation since the last review. Ethical screening: FAIL (changed).

2026-07-18 Distribution $28.90 +0.0% Entry 3

Ethical screening: PASS.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on LKFT

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in LKFT's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $27.45 +4.1% · $1,041 +4.1%
2 months $28.40 +0.6% · $1,006 +0.6%
3 months $31.93 -10.5% · $895 -10.5%
6 months $32.57 -12.3% · $877 -12.3%
1 year $28.31 +0.9% · $1,009 +0.9%
2 years $26.41 +8.2% · $1,082 +8.2%
3 years $43.04 -33.6% · $664 -33.6%
5 years $79.34 -64.0% · $360 -64.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever LKFT does next, these words stay.

Lakefront Biotherapeutics NV · LKFT · Accumulation · $33.31
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.